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Summary 
Notch is a highly conserved transmembrane protein that is involved in cell fate decisions and is 
found in organisms ranging from Drosophila  to humans. A human homologue of Notch, TAN1, 
was initially identified at the chromosomal breakpoint of a subset of T-cell lymphoblastic leu- 
kemias/lymphomas containing a t(7;9) chromosomal translocation; however, its role in onco- 
genesis has been unclear. Using a bone marrow reconstitution assay with cells containing retro- 
virally transduced  TAN1  alleles,  we  analyzed the  oncogenic potential  of both nuclear  and 
extranuclear forms of truncated TAN1 in hematopoietic cells. Although the Moloney leuke- 
mia virus long terminal repeat drives expression in most hematopoietic cell types, retroviruses 
encoding either form of the TAN1 protein induced clonal leukemias of exclusively immature 
T  cell phenotypes in "~  of transplanted animals.  All tumors overexpressed truncated TAN1 
of the size and subcellular localization predicted from the structure of the gene. These results 
show that TAN1 is an oncoprotein and suggest that truncation and overexpression are impor- 
tant determinants of transforming activity. Moreover, the murine tumors caused by TAN1 in 
the bone marrow transplant model are very similar to the TANl-associated human tumors and 
suggest that TAN1 may be specifically oncotropic for T  cells. 
T 
he human TAN1  gene encodes a transmembrane pro- 
tein (TAN1) that contains an extracellular domain pos- 
sessing  a  series  of motifs,  among which  are  iterated epi- 
dermal  growth  factor  (EGF)l-like  repeats,  Notch/lin-12 
repeats, and a pair of evolutionarily conserved cysteine resi- 
dues; the intracellular portion contains ankyrin-like repeats, 
a glutamine-rich region, and a PEST sequence (Fig.  1) (1). 
Each of these motifs is also found in the protein product of 
Notch,  a Drosophila  melanogaster gene that appears to control 
cell fate decisions among equipotent progenitor cells in the 
developing fly (2, 3). TAN1 is expressed at relatively high 
levels in  developing and  adult  thymus,  suggesting  that  it 
might participate in normal T  cell development (1, 3a). 
TAN1  was  originally identified through analysis  of the 
(7;9)(q34;q34.3)  chromosomal translocation found in a subset 
1Abbreviations used in this paper: EGF, epidermal growth factor; FSC, for- 
ward scatter; 5-FU, 5-fluorouracil;  LTI:t.,  long terminal repeat; MoMLV, 
Moloney murine leukemia virus; RIPA, radioimmunoprecipitation  assay; 
SSC, side scatter; SCF, stem cell factor; Su(H), Suppressor of Hairless; 
T-ALL, T cell  lymphoblastic  leukemia/lymphoma;  WBC, white blood  cell. 
of acute human T  cell lymphoblastic leukemias/lymphomas 
(T-ALL) (1, 4). This rearrangement fuses the 3' portion of 
TAN1 on chromosome 9 to the TCP,-[3 locus on chromo- 
some 7. The resulting allele is deleted for most of the cod- 
ing sequence of the extracellular domain of TAN1.  It di- 
rects the synthesis of a series  of truncated polypeptides of 
~-,100-125 kD that have NH2-termini lying near the trans- 
membrane domain (Aster. J., R.. Hasserjian, F. Davi, and J. 
Sklar,  manuscript  submitted  for publication).  The  t(7;9)- 
specific polypeptides localize predominantly to the nucleus, 
probably because of two conserved nuclear localization se- 
quences within the  cytoplasmic domain of TAN1  (Aster, 
J.,  et.  al.,  manuscript  submitted for publication).  Nuclear 
TAN1 has not been detected in cell lines expressing normal 
TAN1  transcripts  or  in  developing murine  thymus  (3a), 
raising  the  possibility  that  altered  subcellular  localization 
might influence transforming activity. 
Although  analysis  of three  tumors  bearing  the  t(7;9) 
showed consistent disruption of  the TAN1 gene at the chro- 
mosomal breakpoint at almost identical positions within the 
gene (1), the contribution of altered TAN1 to transforma- 
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 tion is unknown. One of the three tumors studied, SUP-T1, 
had lost both normal  TANI  alleles, suggesting that  TAN1 
might be a tumor suppressor gene  (1, 5). Alternatively, re- 
moval  of the  extracellular domain  of the  protein  by  the 
translocation might cause constitutive activity of the intra- 
cellular domain, producing a dominant oncoprotein. The lat- 
ter possibility is supported by the results of mutational analysis 
in Drosophila  in which deletions removing the extracellular 
domain  of Notch  have  been  shown  to  lead  to  dominant 
gain-of-function phenotypes,  opposite  to  those  produced 
by loss-of-function mutations  associated with  inactivation 
of the gene (6-8). 
To  examine  whether  TAN1  can  function  as  an  onco- 
protein, we have used recombinant retroviruses to express, 
in  vivo,  proteins  resembling  the  truncated  polypeptides 
found in cells beating t(7;9).  Tumors developed in ~50% 
of mice  that  received bone  marrow  transduced by 5'  de- 
leted forms of TAN1,  In all cases, the tumors were  T  cell 
neoplasms of an immature phenotype. Expression of either 
cytoplasmic or nuclear forms of TAN1  resulted in a nearly 
identical disease. This suggests that transformation by TAN1 
results primarily from overexpression and truncation of the 
protein,  rather  than  subceUular  localization. These  results 
also directly implicate TAN1  in the pathogenesis of t(7;9) 
human T-ALL. 
Materials  and Methods 
Retroviral Vectors and Constructs.  AECT  + and AECT- were con- 
structed by llgatingJK5T, a previously described TAN1 cDNA (1), 
to a PCIL product spanning base pairs -14 to  +70,  which en- 
codes the 5' TAN1 translational start site and signal peptide. Each 
construct was subcloned into the BclI site of the pGD retroviral 
vector  (9).  The  mature  polypeptides encoded by AECT +  and 
AECT- are predicted to be composed of amino acids 1673-2555 
and 1704-2555 and to have NH2-termini located 61 and 30 amino 
acids external to the transmembrane domain, respectively. ICT was 
constructed by ligating an  oligonucleotide containing an ATG 
translational start site to  a  unique  Bsu36I  site within the JK5T 
cDNA. The resultant construct encodes amino acids 1770--2555 
and is predicted to produce a polypeptide consisting of the entire 
intracellular region of TAN1 minus the first  13 amino acids. Se- 
quencing of the 3' long terminal repeat (LTR) ofpGD has shown 
that  it  is  derived  from  the  Moloney  murine  leukemia  virus 
(MoMLV) LTR (M. Scott, unpublished data). 
Retroviral Production and Bone Marrow Infection Protocols.  Transfec- 
tion  of the  retroviral vectors,  cocultivation with  5-fluorouracil 
(5-FU)-treated bone marrow,  and injection into lethally irradi- 
ated BALB/cByJ  recipients were  performed  as  previously de- 
scribed (10).  Cocultivation of the  transfected Bosc23  cells  and 
5-FU-treated bone marrow was performed in a cocktail consist- 
ing of DME,  10% heat-inactivated FBS (JILH Biosciences, Len- 
exa, KS),  5% WEHI-conditioned medium, 6 U/ml recombinant 
mouse  IL-3  (Genzyme Corp.,  Cambridge, MA),  10,000  U/ml 
recombinant mouse IL-6 (Genzyme), 5U/ml recombinant mouse 
stem  cell factor  (SCF)  (Genzyme),  1 ~g/ml  polybrene (Sigma 
Chemical Co., St. Louis, MO), 100 U/ml streptomycin (GIBCO 
BRL,  Gaithersburg, MD),  100  U/ml penicillin (GIBCO BILL), 
and 2  mM t-glutamine (GIBCO BILL).  Between 5  ￿  10  s and 
1 ￿  10  6 nonadherent cells were injected into a tail vein of each 
recipient animal. Bone marrow and spleen cells from all tumors 
were cultured in DME supplemented with 20% heat-inactivated 
FBS 0ILH Biosciences), 100 U/ml streptomycin (GIBCO BRL), 
100 U/nil penicillin (GIBCO BILL), 2 mM L-glutamine (GIBCO 
BR.L),  and 4 U/ml recombinant mouse IL-2 (Genzyme). Bone 
marrow cells derived from mice T6, I8, and I22 adapted to con- 
tinuous  in  vitro  growth.  Tumor  cells  from  all AECT  animals 
were readily transplantable to syngeneic mice.  Transfer of ICT 
tumors to secondary recipients was not attempted.  BALB/cByJ 
mice were obtained from Jackson Laboratories (Bar Harbor, ME) 
and maintained at the animal facilities at Rockefeller University 
and Massachusetts  Institute of Technology under specific patho- 
gen-flee conditions. 
Protein Analysis  and Immunohistochemistry.  kadioimmunopre- 
cipitation assay (ILIPA) extracts (11) were prepared from cell lines 
and tumors, and 10 Izg of  protein was subjected to electrophoresis 
in  6%  discontinuous  SDS-polyacrylamide gels  and  then  trans- 
ferred electrophoretically to nitrocellulose membranes. The blot 
was  probed with  affinity-purified polyclonal rabbit anti-TAN1 
raised against the T3  region of the cytoplasmic domain (Fig.  1) 
and developed by a chemiluminescent method (Amersham Inter- 
national, Little Chalfont, Buckinghamshire, UK). DNA encoding 
a portion of TAN1 termed T3 (codons 1733-1877) was amplified 
by PCIL from JK5T (1), ligated into the vector pGEX-4T (Phar- 
macia), and subsequently purified from detergent lysates with glu- 
tathione-Sepharose beads  (Pharmacia Biotech,  Inc.,  Piscataway, 
NJ)  (11). Serum from immunized rabbits was affinity purified by 
sequential passage  over  an  AflqGel-15-GST column  (Bio-iLad 
Laboratories, Hercules, CA) and an AflqGel 15-GST-T3 column. 
For immunohistochemistry, sections cut from paraffin-embedded 
tissue were deparaffinized and boiled in a 5% urea solution for 10 
min (12).  Immunoperoxidase staining was performed with affin- 
ity-purified rabbit anti-T3  according to  a  previously described 
method  (13).  Slides were counterstained with hematoxylin. For 
staining of T6E and I22 cells, the cells were allowed to adhere to 
poly-r-lysine-coated slides,  fixed in  3%  paraformaldehyde, and 
permeabilized with  0.1%  saponin.  Indirect  imnmnofluorescent 
and  immunoperoxidase  staining  was  performed  with  affinity- 
purified anti-T3  and  secondary anti-rabbit antibody linked to 
FITC (Sigma) or HRP (Sigma), respectively. 
Flow Cytometry.  Spleen cells or LN cells were obtained from 
mice T8A1, I8, T3A2, T7, or age-matched controls and analyzed 
for forward scatter (FSC), side scatter (SSC),  and expression of 
Thyl.2, CD4, and CD8 by multiparameter flow cytometry as de- 
scribed (14).  For each animal, FACS  |  analysis was performed on 
tumor samples derived from at least two different sites, and in all 
cases, results from the different sites were concordant  (data not 
shown).  Control  spleen  was  obtained  from  an  age-matched 
BALB/cByJ  mouse.  T8A1  spleen  cells  were  derived  from  a 
mouse that had received 10 s T8 tumor cells, and T3A2 LN cells 
were derived from a mouse that had received 105 T3 bone mar- 
row cells. The staining patterns of the primary T8 and T3 tumors 
were very similar to the patterns found in T8A1 and T3A2. Anti- 
bodies used were the following: CDSa-FITC (YTS169.4;  Caltag 
Laboratories, San Francisco, CA), CD4-PE  (YTS191.1;  Caltag), 
TCtM3-PE  (H57-597;  Caltag),  TCRy/8-PE  (GL3;  Caltag), 
Thyl.2-FITC  (5a-8;  Caltag),  CD3-FITC  (500-A2;  Caltag), 
B220-PE (RA3-6B2; Caltag), MAC-1-PE (M1/70.15; Caltag), and 
CD24-PE  (M1/69;  PharMingen, San Diego, CA). Fluorescence 
was analyzed on a FACScan  |  flow cytometer with CellQuest soft- 
ware (Becton Dickinson, San Jose, CA). 
DNA Analysis.  High  molecular weight  DNA  was  isolated 
from fresh or snap-frozen tissues,  digested with appropriate re- 
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 striction  enzymes, and analyzed by Southern blot hybridization as 
previously described  (10). For each animal,  DNA was prepared 
from tumors from at  least  two different  sites. In each case, the 
proviral  integration  patterns  were  identical  in  the  tissues from 
multiple sites (data not shown). 
Results 
Retroviral  Expression  of Truncated  TAN1  in  Murine  Bone 
Marrow Induces  T-cell Neoplasms.  To  assess  the  transform- 
ing  potential  of truncated  TAN1  in  hematopoietic  cells, 
three  TAN1  cDNA  constructs  (Fig.  1)  were  cloned  into 
the  pGD  retroviral  vector  (9).  This  retroviral  vector  ex- 
presses the truncated  TAN1 gene under the control of the 
promoter dements of the MoMLV LTR.. Two constructs, 
AECT +  and  AECT-,  encoded polypeptides  consisting  of 
the TAN1 signal peptide fused to sequences just external to 
the transmembrane domain. The major difference between 
these two polypeptides was that one retained a pair of evo- 
lutionarily  conserved  extracellular  cysteines  (AECT+), 
whereas  the  other  did  not  (AECT-).  Both  of these  con- 
structs produced polypeptides that localized predominantly 
to endoplasmic reticulum and nuclear membrane when sta- 
bly overexpressed in NIH 3T3 cells  (Aster, J., unpublished 
data). The third construct, ICT, encoded most of the cyto- 
plasmic  domain of TAN1  and showed predominantly nu- 
clear localization when  transiently  or stably overexpressed 
in  murine  fibroblasts  (Aster, J.,  unpublished  data).  These 
forms were chosen for three  reasons.  First,  the  size of the 
encoded polypeptides  (~120  kD for the  AECT polypep- 
tides and ~110 kD for ICT) roughly resembles that of the 
polypeptides found in cells bearing the t(7;9).  Second, the 
different  subcellular  localization  of the  encoded  polypep- 
tides serves to test the importance of nuclear localization in 
transformation. Finally, comparison of AECT  + and AECT- 
might  identify  a  role  for the  conserved  extracellular  cys- 
teine  residues  in  transformation,  a  possibility suggested by 
the  observation that mutation  of either  of these  two resi- 
dues  in Notch produced a  gain-of-function phenotype in 
the fly (8). 
These  TAN1  constructs  were  individually  transfected 
into  the  ecotropic  retroviral  packaging  line,  Bosc23,  and 
the resulting high titer retroviral supematants were used to 
infect BALB/cByJ bone marrow in vitro  (10).  10 lethally 
irradiated  syngeneic  mice received  bone  marrow infected 
with each construct. From 11  to 40 wk after transplant,  11 
mice showed sudden onset cachexia and increases in their 
white  blood  cell  (WBC)  counts  coincident  with  the  ap- 
pearance  of leukemic  blasts  in the  peripheral  blood.  One 
additional  mouse,  T3,  became cachectic and had circulat- 
ing blasts without increased WBCs (Table 1). Tumors arose 
in  four  mice  receiving  AECT +  bone  marrow,  in  three 
mice receiving AECT- marrow, and in five mice receiving 
ICT  marrow,  suggesting  that  the  tumorigenicity  of each 
construct was approximately equivalent.  This suggests that 
the presence or absence of the  conserved extracellular pair 
of cysteine residues does not influence transforming activ- 
ity. The observed frequency with which tumors arose (30- 
50%)  is probably less  than  the  actual frequency,  as  several 
sudden and unwitnessed deaths occurred in each group. 
At necropsy, five of the mice had thymic masses,  while 
seven mice contained only thymic remnants,  the latter be- 
ing consistent with postirradiation involution (Table  1).  I0 
of 12 mice had lymphadenopathy and marked hepatosple- 
nomegaly secondary to extensive infiltration and distortion 
by leukemic  blasts  (not shown).  The  remaining  two  ani- 
mals,  T3 and I9, had microscopic leukemic cell infiltration 
of spleen and liver. 
TAN l-associated  Tumors  are  Composed of Immature  T  cells. 
Flow cytometric  analysis  showed  that  each  of the  12  tu- 
mors was composed of immature T  cells (Fig. 2). While all 
12  tumors  reacted  with  antibodies  to  Thyl.2  (Fig.  2  and 
data not shown) and TCP,-[3 chain (not shown), individual 
tumors  showed  variable  patterns  of reactivity  with  anti- 
TAN-1 
pGD AECT+ 
pGD AECT- 
pGD ICT 
I  I 
aT3 
X 
X  TI 
I  I 
QPI 
R  X 
R  X 
X  I22  R  I21  X 
Figure  1.  Structure of TAN1 and AECT and 
ICT cDNA constructs used in the bone marrow 
transplant experiments. The  arrow indicates the 
approximate site at which the TAN1 cDNA se- 
quence is disrupted by recombination of TAN1 
with TCR-I8 in tumors with t(7;9) (q34; q34.3) 
(1). The deletion in T1 occurred 5' to the cDNA 
insert in the pGD vector and is indicated by T1. 
The deletion in [21 occurred 3' to the cDNA in- 
sert in the pGD vector and is indicated by I21 and 
the deletion in I22 occurred 5' to the cDNA in- 
sert in the pGD vector and is indicated by I22. 
The T3 region of TAN1 used for immunization 
is underlined. Legend: black, hydrophobic leader; 
stippled,  EGF-like repeats; diagonally striped, 
LNt< repeats; C~ paired, conserved cysteines resi- 
dues located 49 and 42 amino acids external to 
the  transmembrane  domain; black but  with 
extended lines, transmembrane domain; dotted, 
ankyrin repeats; Q,  glutamine-rich region;  P, 
PEST sequence; X, XbaI; R, EcoRl.  The Mo- 
MLV LTP,. and neo resistance gene of the pGD 
retroviral vector are indicated. 
2285  Pear et al. 
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 Table 1.  Summary of Tumors in TAN1  Transplants 
Latency  Terminal  Thyrnic 
Animal  Construct  (weeks)  WBC/mm  3  involvement 
Balb/c 
Spleen 
T1  AECT--  11  70  No 
T3  AECT-  16  4  No  TSA1 
Spleen 
T4  AECT--  t2  68  No 
T6  AECT+  15  42  Yes 
T7  diECT+  40  65  Yes 
T8  dtECT+  15  41  No  I8 
Spleen 
T14  AECT+  16  55  Yes 
I8  ICT  25  25  Yes 
I9  ICT  25  32  No 
I21  ICT  18  40  No  TaA2 
I22  ICT  18  50  No  Node 
I46  ICT  21  150  Yes 
CD4 and anti-CD8.  The observed immunophenotypes re- 
vealed cell populations ranging from predominantly Thyl.2 + 
CD4- CDS- double negative cells  (Fig. 2, T7), resembling 
immature  cortical  thymocytes,  to  predominantly  Thyl.2 + 
CD4 +  CD8 +  double positive  cells  (Fig.  2,  T8A1  and  I8, 
and  also  T1,  T4,  19,  and  I46  [not shown]),  resembling  a 
more  mature  cortical thymocytic phenotype.  Five  tumors 
(T3,  T6,  T14,  I21, and  I22)  expressed high levels of CD8 
and  lower  levels  of  CD4  (Fig.  2,  T3A2  and  data  not 
shown),  compatible with a maturation stage between dou- 
ble-negative  and double-positive  cells  (15,  16). Additional 
studies  showed that cell lines derived from several of these 
tumors (T6, I8, and I22) had intermediate to high level sur- 
face expression of CD24 (heat stable antigen) and expressed 
RAG-2  (Pear,  W.,  unpublished  data),  features  also shared 
by normal cortical thymocytes (17,  18). R.AG-2 expression 
was also observed in liver infiltrated by the T3 and T7 tu- 
mors  (Pear,  W.,  unpublished  data).  As  exemplified  by  I8 
and T3A2 (Fig. 2), some tumors contained several subpop- 
ulations of cells with distinct immunophenotypes. 
TANl-induced  Tumors  Contain  Integrated  Proviruses  and 
Overexpress  Truncated Forms of TAN1.  All tumors contained 
integrated  proviruses,  as  shown  by Southern  (DNA)  blot 
analysis (Figs.  3 a and 4 a). The proviral structure was intact 
in nine  tumors,  while  three  contained small  deletions  that 
mapped within vector sequences flanking the cDNA inserts 
(see  Fig.  1).  Further blot analysis showed that  10 of 11  tu- 
mors that could be evaluated contained a single integrated 
provirus,  while  one  tumor,  T3,  contained  two  unique 
proviral  sequences  (Figs.  3  b,  4  b,  and  data  not  shown). 
Clonal TC1K J[32 rearrangements were observed in 9 of 11 
tumors evaluated (Figs.  3 c and 4 c). Because tumor infiltra- 
tion in the  spleen and liver of the I9 mouse was minimal, 
this  tumor could not be  evaluated for proviral  integration 
number or TC1K-[3 rearrangement. 
All  of the  tumors  expressed  the  introduced  truncated 
[  t 
T7 
Spleen 
L  L  E  I 
I  I  I  1  t 
FSC 
.....  .I  ......  i  ......  I  .....  i 
..... 
iza  "r'-  I 
v 
Thyl.2 
ar 
ca 
8 
CD8 
Figure  2.  Immunophenotyping of" TANl-associated tumors by flow 
cytometry. Two-parameter contour plots show FSC versus SSC (left) and 
CD4 versus CD8 expression (right). Cursors on the right were set on the 
basis of  profiles of  normal splenocytes  and thymocytes.  A single-parameter 
histogram shows the expression of Thyl.2 (solid lines, center  column). The 
dotted line in the upper panel shows Thyl.2 expression in unstained con- 
trol spleen cells. The tumors were negative for macrophage (Mac-l) and 
B-cell (13220) markers, as well as for expression of TCR.-y/8.  In all tu- 
mors, the majority of cells expressed TCR.-ot/~ and low levels of CD3. 
forms of TAN1  at high levels relative  to the levels of en- 
dogenous murine  TAN1  (Notch1)  in normal BALB/cByJ 
thymus, spleen, and liver, and the T  cell line AKR (Figs. 5 
a and 5 b, and data not shown). BALB/c thymus contained 
a protein of~120  kD (p120)  (Fig. 5 a) that is derived from 
full-length TAN1 by proteolytic cleavage at a site just  ex- 
ternal  to  the  transmembrane  domain  (Aster,  J.,  et  al., 
manuscript  submitted  for publication),  p120  is  closely re- 
lated in primary structure  to both the  t(7;9)-specific poly- 
peptides  and  the  AECT-encoded  polypeptides.  It  is  also 
overexpressed by tissue culture cells  transduced by a retro- 
virus  carrying a  full-length  TAN1  cDNA,  indicating  that 
full-length TAN1  serves as a precursor molecule for p120 
(19, Aster, J. et al.,  submitted).  Despite its structural resem- 
blance to oncogenic forms of truncated TAN1, p120 does 
not appear to be oncogenic, since none of 10 mice receiv- 
ing bone marrow infected with a retrovirus expressing full- 
length TAN1 developed TANl-expressing tumors over the 
course of 1 yr (Pear, W., andJ. Aster, unpublished data). 
Both  Cytoplasmic  and  Nuclear Forms of TAN1  Are  Onco- 
genic.  Microscopic examination of pathologically enlarged 
spleen,  liver,  and  LNs  showed  infiltration  by  leukemic 
blasts  (Fig. 6 a,  and data not shown).  Immunohistochemis- 
2286  T-ALL Induction by TAN-1 
 
o
n
 
D
e
c
e
m
b
e
r
 
2
9
,
 
2
0
0
6
 
w
w
w
.
j
e
m
.
o
r
g
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 try performed on these tissue sections showed a high level 
of TAN1  expression in tumor cells relative to levels in sur- 
rounding normal tissue (Fig. 6  b, and data not shown). Sub- 
cellular localization of TAN1  was  further  investigated in 
disaggregated tumor  and  cell lines.  Tumors  induced with 
either  AECT  construct  showed  prominent  cytoplasmic 
staining with TANl-specific antibodies (Fig. 6  c,  and data 
not  shown).  This  staining  colocalized with  that  observed 
using antibodies against calnexin, a protein previously shown 
to localize to the endoplasmic reticulum (20). This suggests 
that most  AECT-produced TAN1  is present in the endo- 
plasmic reticulum  and  contiguous portions  of the  nuclear 
membrane.  In  contrast,  tumors  induced by the  ICT  con- 
struct showed strong nuclear staining (Fig. 6  d, and data not 
shown). 
Discussion 
These  studies  show  that  truncated  forms  of TAN1  can 
induce  T  cell  tumors  in  mice,  strongly  suggesting  that 
Notch homologues can function as human oncogenes. Two 
findings support  a  direct role  for  truncated  TAN1  in  the 
pathogenesis  of the  murine  T  cell  neoplasms.  First, high 
level  expression  of the  proteins  encoded  by  retrovirally 
transmitted  TAN1  cDNAs  occurred  in  all analyzable tu- 
mors.  Second, a  single integrated provirus was detected in 
most of the tumors, which were readily passaged in synge- 
neic recipients. 
The current data, together with our previous experience 
using the bone marrow transplant assay, argue against other 
explanations for the high frequency of T  cell malignancies 
observed in these animals. First, insertional mutagenesis by 
replication-competent helper virus  seems  unlikely,  as  the 
MoMLV  envelope  gene  was  absent  from  the  malignant 
cells  (Pear,  W.,  unpublished  data).  Second,  activation  of 
leukemogenic  endogenous  retroviruses  by  the  marrow 
transfer procedure itself is quite rare.  Using bone  marrow 
infected  with  retroviruses  that  carry  different  oncogenic 
and nononcogenic cDNA inserts, we have transplanted over 
200 BALB/c mice. Of these animals, which have been fol- 
lowed for more than 1 yr after transplant, only one has de- 
veloped a  T  cell malignancy (Pear W.,  and M.  Scott, un- 
published data). 
The  T  cell  specificity  of transformation  by  TAN1  is 
striking  and  probably  results  from  the  properties  of the 
Figure 3.  Analysis  of TANI proviral integration and TCR-~ chain re- 
arrangement in dIECT tumors. (A) Southern blot of XbaI-digested ge- 
nomic DNA hybridized with  TAN1 cDNA. XbaI cleaves once in each 
LTR (Fig. 1), generating a 6-kb fragment after hybridization to a TAN1 
probe. The 4.4-kb fragment is the endogenous Notch1 fragment. Lanes: 
T6E cell line, T6 thymus, T7 thymus, BALB/c liver, T1  salivary gland, 
T3 spleen, T4 spleen, T7 spleen, T8 thigh mass, T14 spleen. (B) Southern 
blot of EcoRI-digested  genomic DNA hybridized with  TANI  cDNA. 
EcoRI cleaves once in the pGD AECT vectors (see Fig. 1). Lanes: T6E 
cell line, T6 thymus, T7 thymus, BALB/c liver, T1 spleen, T3 spleen, T4 
spleen, T7 spleen, T8 thigh mass, T14 spleen. The TAN1 hybridization 
probe in both A and B was a 561-bp fragment that was derived by PCR 
from a region of the cDNA 3' of the ankyrin repeats (base pairs 6832- 
7393). (C) TCR I~ rearrangement in AECT tumors. DNA was digested 
with HindlIl. The hybridization probe is the 2,2-kb EcoRI TCR-JJ32- 
specific DNA fragment (37) that hybridizes to a 5-kb HindlII fragment in 
unrearranged DNA.  Lanes: BALB/c  liver, T1  spleen, T3  spleen, T4 
spleen, T7 spleen, T8 thigh mass, T14 spleen, T6E cell hne. 5-10 ~g of 
DNA was loaded in each lane except T6 thymus, where 2 ~g was loaded. 
Size markers, in kilobases,  are to the left. 
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 Figure 4.  Analysis of TAN1 proviral integration and TCR-13 chain rearrangement in ICT tumors.  (A) Southern blot ofXbal-digested genomic DNA 
hybridized with TAN1 cDNA. XbaI cleaves once in each LTP, (see Fig.  1), generating a 5.8-kb fragment after hybridization to a TAN1 probe. The 4.4- 
kb fragment is the endogenous Notch1 fragment. The smaller bands in I21 spleen (lane 5) and I22 spleen and cell line (lanes 6 and 7) are the result of de- 
letions occurring outside of the TAN1  cDNA in the integrated provirus (Fig.  1). Lanes:  I, BALB/c liver; 2, I8 cell line; 3, I8 spleen; 4, I9 spleen; 5, 121 
spleen; 6, I22 spleen; 7, I22 cell line; 8, I46 spleen. (B) Southern blot of HindlII-digested genomic DNA hybridized with TANI cDNA.  HindlII cleaves 
outside of the pGD ICT  vector.  The 3-kb and ~  bands are endogenous murine Notch  sequences.  Lanes:  1, BALB/c liver; 2,  I22 spleen; 3,  146 
spleen. The TAN1 hybridization probe in A and B was a 561-bp fragment that was derived by PCP- from a region of the cDNA 3' of the ankyrin repeats 
(base pairs 6832-7393).  (C-') TCR-~8 rearrangement in ICT tumors. DNA was digested with EcoP, l. The hybridization probe is the 2.2-kb EcoRI  TCR- 
//B2-specific DNA  fragment  (37)  that hybridizes to a 2.2-kb EcoPd  fragment in cells that have not undergone  rearrangement of this locus.  Lanes:  1, 
BALB/c liver; 2, I8 spleen; 3, I9 spleen; 4, 121 spleen; 5, I22 spleen; 6, I46 spleen. 5-10 Ixg of DNA was loaded in each lane. Size markers, in kilobases, 
are to the left. 
TAN1  gene  product  itself and  not  from  its  route  of intro- 
duction.  The  MoMLV  LTR  in  the  pGD  vector  directs 
high  level  transcription  in  a  wide  variety  of hematopoietic 
cell  types.  Infection  of whole  bone  marrow  targets  all  di- 
viding  ceils,  not  just  T  cell  progenitors  (21).  In  previous 
transplants  using  sintilar protocols,  but  different  transform- 
ing  genes,  tumors  of pre-B  cell,  granulocyte,  macrophage, 
and mast cell origin occurred  (9,  22-24).  The  T  cell  onco- 
tropism  of TAN1  distinguishes  it from  the  product  of int3, 
a  distantly  related  member  of the  Notch  family.  This  gene 
is  associated  with  murine  salivary  and  mammary  tumors, 
apparently  owing  to  the  specificity  of the  mouse  mammary 
tumor  virus  promoter,  which  controls  transcription  of the 
gene  (25). 
Figure  5.  TAN1  protein  expression  in  AECT  and 
ICT tumors.  (A) Western blot showing  TAN1  expres- 
sion  in  tumors  from  AECT  transplants.  The  AECT 
TAN1  specific  product  is  present  at  ~120  kD.  The 
band at ~350  kl) in the T6E lane corresponds in size 
to the product  of murine Notch1  (38). A  faint band in 
the identical position was observed in all other AECT 
tumor  extracts  upon  longer  exposure  (not  shown). 
Lanes: Jurkat, a human T-ALL with apparently nomaal 
TAN1  alleles,  SUPTI,  a human T-ALL  cell line with 
two  copies of the  t(7;9)  and no  normal  TANI  allele, 
BALB/cByJ thymus, T1  spleen, T3B2 spleen (second- 
ary  transplant  recipient  of cells  from  T3  spleen),  T4 
spleen,  T6  thymus,  T6E  cell  line,  T8  thigh  mass, 
TI4A1  spleen  (secondary  transplant  recipient  of cells 
from  TI4  spleen).  (B)  Western  blot  showing  TAN1 
expression  in tumors  from  ICT  transplants.  The  ICT 
TANI  specific product is present at ~110 kD. A simi- 
lar band  was  present  in  146  spleen  (Aster, J.,  unpub- 
lished data). The HI 10-kD band was not detectable in 
19 spleen owing to the small amount of tumor present 
in  the  liver  and  spleen  of this  animal.  The  band  at 
~'350 kD in the I22 cell line (lane 5) corresponds in size to the product of murine Notchl  (38). A faint band in the identical position was observed in all 
other ICT  tumor extracts upon longer exposure.  The ~120-kD  TANl-specific  band corresponding to the proteolytic  cleavage product  is present in 
BALB/c thymus upon longer exposure. Lanes:  1, BALB/c spleen; 2, BALB/c thymus; 3, I2I liver; 4, I22 spleen; 5, I22 cell line; 6, I8 liver;  7, 18 spleen; 
8, I9, spleen.  10 I*g of protein was loaded in each lane. The size markers, in kD, are to the left. 
2288  T-ALL  Induction by TAN-1 
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 Figure  6.  Immunohistochemical local- 
ization of AECT and ICT proteins in tu- 
mors and  cell lines.  (A)  Microscopic ap- 
pearance of  a representative AECT tumor. 
A portion of the enlarged spleen of  animal 
T7 was paraffin-embedded and sectioned. 
The slides were stained with hematoxylin 
and eosin. Normal splenic architecture is 
replaced by a  monomorphous population 
of blasts.  (B}  Immunoperoxidase staimng 
showing  TAN1  expression  in  leukemic 
blasts infiltrating the liver of  animal T7 (he- 
matoxylin counterstain). (C)  Immunoflu- 
orescent localization of  TAN1 in T6E cells. 
(D)  Immunoperoxidase staining of TAN1 
in I22 cells (without counterstaining). 
2289  Pear et al. 
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 Unlike several other genes implicated in the pathogene- 
sis  of T-ALL,  including  TALI,  RBTN2,  and  HOX11, 
which  are not  normally  expressed in  thymocytes  (26-29), 
Notch 1~TAN1 is expressed at high levels in normal thymus 
(1)  and  is  also  expressed  in  CD34 +  stem  cells  within  the 
bone marrow (30). The highest levels of TAN1  expression 
in routine and human thymus occur in cortical thymocytes 
(3a),  and  all  of the  TANl-associated  tumors  described  in 
this  report  have  immunophenotypes  resembling  those  of 
normal cortical thymocytes. The normal function of TAN1 
in T  cells and marrow progenitor cells is unknown.  How- 
ever,  recent  developmental  studies  in flies,  frogs,  and  cul- 
tured  routine  cells  have  shown  that  truncated  forms  of 
Notch-related proteins inhibit certain programs of differen- 
tiation  (2).  For example, truncated  Notch1  inhibits  neuro- 
genesis  and  myogenesis  of routine  embryonal  carcinoma 
cells  (31,  32).  These  and  other  observations  support  the 
idea that Notch expression maintains various cell types in a 
less  differentiated  state  (3,  33).  Our  studies  suggest  that 
truncated  TAN1  might  act  in  a  similar  fashion  within  T 
cell progenitors by preventing their terminal differentiation 
and predisposing them to malignant transformation. 
The apparent ability of truncated TAN1  to transform re- 
gardless ofsubcellular localization is puzzling, Although it is 
possible that a small amount of nuclear protein in the AECT 
tumors  is  responsible  for  transforming  activity  (or  that  a 
small amount of cytoplasmic protein is culpable in ICT tu- 
mors), it is noteworthy that functional equivalence of cyto- 
plasmic and nuclear forms of truncated Notch has also been 
observed in  a  number  of other  systems,  particularly  those 
assessing effects on  eye,  wing,  and  bristle  development  in 
the  fly  (7,  8).  AECT-like  polypeptides  also perturb  myo- 
genesis  and  neurogenesis  in  developing  frogs  (34).  One 
possible explanation for the functional equivalence of cyto- 
plasmic and nuclear Notch proteins would involve interac- 
tion  with  downstream  factors  that  normally  shuttle  be- 
tween  the  nucleus  and  the  cytoplasm.  Candidate  proteins 
include  several transcription  factors that are believed to in- 
teract with Notch  on on the basis of genetic  data  (2).  The 
subcellular localization of one molecule, Suppressor of Hair- 
less  (Su(H)), appears to be controlled by activation of Notch 
through binding ofligand to the extracellular domain.  This 
suggests that Su(H) participates in Notch signaling in some 
cell types in the fly (35). A mammalian homologue of Su(H), 
CBFI  (also  known  as  RBP-J  kappa),  has  been  shown  to 
activate  transcription  following  interaction  with  murine 
Notch1  (36).  Preliminary results show that Su(H)  interacts 
with both the  AECT  and  ICT proteins  (Aster, J.,  unpub- 
lished  data),  suggesting  that  this  molecule  is  involved  in 
neoplastic  signaling  in  these  tumors.  Elucidation  of this 
signalling  pathway  and  the  activated  genes  awaits  further 
analysis. 
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